|1.||Chantarangkul, Veena: 3 articles (08/2013 - 07/2010)|
|2.||Lemma, Laura: 3 articles (08/2013 - 07/2010)|
|3.||Tripodi, Armando: 3 articles (08/2013 - 07/2010)|
|4.||Mannucci, Pier Mannuccio: 3 articles (08/2013 - 07/2010)|
|5.||Primignani, Massimo: 2 articles (08/2013 - 07/2010)|
|6.||Xia, Shu-Jie: 2 articles (12/2009 - 01/2009)|
|7.||Sun, Xiao-Wen: 2 articles (12/2009 - 01/2009)|
|8.||Han, Bang-Min: 2 articles (12/2009 - 01/2009)|
|9.||Tang, Yue-Qing: 2 articles (12/2009 - 01/2009)|
|10.||Hong, Yan: 2 articles (12/2009 - 01/2009)|
|2.||Activated Protein C Resistance (APC Resistance)
06/01/1999 - "The platelet-dependent APC resistance phenotype was also observed when endogenous APC was generated by Protac (American Diagnostica, Inc, Greenwich, CT). "
05/01/2001 - "Protein C (PC) and activated PC (APC) resistance can be measured by means of RVV, Protac (from Southern copperhead snake venom) and STA-Staclot (from Crotalus viridis helleri) whilst von Willebrand factor can be studied with Botrocetin (Bothrops jararaca). "
06/15/2005 - "Protein C and activated protein C resistance can be measured by means of RVV and Protac, a fast acting inhibitor from Southern copperhead snake venom and von Willebrand factor can be studied with botrocetin from Bothrops jararaca venom. "
07/01/1998 - "Protein C and activated protein C resistance can be measured by means of RVV and Protac, a fast acting inhibitor from Southern copperhead snake venom and von Willebrand factor can be studied with Botrocetin from Bothrops jararaca venom. "
01/01/2005 - "Pentasaccharide and Protac had a synergistic effect resulting in a clearly reduced coagulation in the normal controls, but less in persons with thrombophilia. "
12/15/2002 - "The original overall haemostatic potential assay and our modified version with Protac and pentasaccharide to enhance inhibition by activation of protein C and by antithrombin (AT) were performed in plasma from 18 persons with thrombophilia. "
07/01/2010 - "We sought to assess this hypercoagulability with a simpler thrombin-generation assay performed in the presence/absence of Protac, a snake venom that activates protein C in a manner similar to thrombomodulin (new assay). "
|4.||Prostatic Neoplasms (Prostate Cancer)
12/04/2008 - "Similarly, Protac-A treatment of androgen-dependent prostate cancer cells induced G(1) arrest but did not affect cells that do not express AR. "
12/01/2009 - "To investigate targeted degradation of the androgen receptor (AR) by chimeric molecules (DHT-PROTAC) via the ubiquitin-proteasome pathway in androgen-independent prostate cancer CA-2B cells, and explore the proliferation, secretion and apoptosis of the treated cells. "
01/01/2009 - "We employed chimeric molecules (dihydrotestosterone-based proteolysis-targeting chimeric molecule [DHT-PROTAC]) to facilitate androgen receptor (AR) degradation via the ubiquitin-proteasome pathway (UPP) and to investigate the role of AR in cell proliferation and viability in androgen-sensitive prostate cancer cells. "
09/01/2010 - "Both the ETP with Protac(®) and the ETP ratio were increased in cirrhosis (mean 1074 ± 461.4 vs. 818 ± 357.9 nM min, P = 0.004 and 0.80 ± 0.21 vs. 0.44 ± 0.15, P ≤ 0.0001, respectively). "
07/01/2010 - "The median(range) PICI% was lower in patients (74% [31%-97%]) than controls (93% [72%-99%]; P < 0.001), indicating that patients with cirrhosis are resistant to the action of Protac. "
08/01/2013 - "Cirrhosis is associated with a plasmatic procoagulant imbalance, detected in vitro by thrombin generation tests performed in the presence vs. absence of such activators of protein C as thrombomodulin or Protac. "
|2.||Snake Venoms (Snake Venom)
|4.||Proteasome Endopeptidase Complex (Proteasome)
|6.||von Willebrand Factor
|7.||Androgen Receptors (Androgen Receptor)